LDL

Sepsis - Pipeline Insight, 2022: Innovations from SciClone, Sanofi, BioAegis & More Set to Transform Sepsis Treatment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 8, 2023
Health, Clinical Trials, Route, Protein, Cholesterol, COVID, Intensive care medicine, Infection, III, Therapy, Vaccine, Pneumonia, Cell, News, HCV, Clinical trial, Discovery, Bacterial pneumonia, Bacteria, Artery, Administration, Liver cancer, Patient, PCSK9, Risk, Heparin, Thymosin, Survival, Route of administration, Immunotherapy, Melanoma, Alirocumab, HBV, Cancer, Inflammation, LDL, Histone, Fungal infection, Hepatitis B virus, Pharmaceutical industry, Medical device, Sepsis

This "Sepsis- Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This "Sepsis- Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

Retrieved on: 
Friday, March 3, 2023
Patient, MTV: TRL Christmas, Physiology, RNA, LDL, Clinical trial, ANGPTL3, PCSK9, DNA, Blood, Liver, Triglyceride, LDLR, LNP (newspaper), NHP, Primate, Asialoglycoprotein receptor, Initiation, ASCVD, Cardiovascular disease, LNP, Drug, Vaccine, Copper, Dietary supplement, Mouse, Verve

BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported new preclinical data in non-human primates (NHPs) demonstrating potent, durable and well-tolerated editing of the ANGPTL3 gene following administration of VERVE-201.

Key Points: 
  • “ASCVD is not only a devastating but also a challenging group of indications to treat, requiring multiple treatment options for patients.
  • Patients with HoFH have severe or complete LDLR deficiency, which limits the ability of traditional LNPs to deliver base editing medicines to the liver.
  • Verve first developed LDLR-deficient NHPs (n=4), resulting in an increase in mean LDL-C from 55 to 458 mg/dL.
  • Presentation Title: Preclinical Data Supporting Potential Efficacy of Verve-201 - An Investigational CRISPR Base Editing Medicine Targeting ANGPTL3 - In Primary Human Cells, Mice, And Non-Human Primates

Family Heart Foundation Real-World Analysis Reveals That Majority of Americans at High Risk of Stroke and Heart Attack Remain Under-Treated

Retrieved on: 
Tuesday, February 28, 2023
Science, Cardiology, Other Science, Research, General Health, Health, Philanthropy, Foundation, Congress, American College, LDL, Patient, Insurance, Cardiovascular disease, Public, Risk, Observational study, ASCVD, Moyamoya disease, Guideline, Splenic infarction, Ernest, Poster, Pharmaceutical industry

This may be due to a lack of physician prescribing, insurance coverage and patient follow through, despite the known risk of cardiovascular disease.

Key Points: 
  • This may be due to a lack of physician prescribing, insurance coverage and patient follow through, despite the known risk of cardiovascular disease.
  • Additional key findings from the study show:
    Only 27.8% of all high-risk patients ever reached below-guideline LDL-C thresholds.
  • 79.5% of clinicians never prescribed combination cholesterol-lowering medications though the guideline provides direction and rational for doing so.
  • The Family Heart Database is comprised of real-world diagnostic, procedural, and prescription data from claims and/or laboratory information in the U.S. from 2012 to 2021.

Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar

Retrieved on: 
Thursday, February 23, 2023
Research, Fitness & Nutrition, Cardiology, Other Natural Resources, Other Health, Biotechnology, Health, Natural Resources, Science, Other Science, Development, Research and development, European Regional Development Fund, LDL, Annual report, European, Letter, Risk, Shareholder, R, ERDF, Prediabetes, Acceleration, PEA, BPI, AMF, DSM-IV codes, Phase, CSR, Dietary supplement, Pharmaceutical industry, Security (finance), Rare-earth element, Cryptocurrency

Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today publishes its 2023 Letter to Shareholders including its 2023 financial calendar.

Key Points: 
  • Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today publishes its 2023 Letter to Shareholders including its 2023 financial calendar.
  • Valbiotis also announces its financial calendar for 2023:
    March 15: publication of the 2022 Annual Report;
    September 28: publication of the 2023 Half-Yearly Report.
  • Due to environmental considerations, as part of our commitments, our “Letter to Shareholders” will now be offered in digital format only: Letter to Shareholders No.6 .
  • Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time.

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity

Retrieved on: 
Thursday, February 23, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, TTR, Randomness, Brazilian Health Regulatory Agency, PDUFA, Patisiran, LDL, Polyneuropathy, ATTR, Hypercholesterolemia, Agency, European Medicines Agency, Amyloidosis, FDA, Patient, Bachelor of Medicine, Bachelor of Surgery, CNS, RTE, Growth, Plasma, Therapy, ANVISA, EMA, Type, Cardiomyopathy, Medication, KARDIA, Prescription Drug User Fee Act, Novartis, PH1, RNA interference, Pharmaceutical industry, Video game, Pigment, Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights.
  • Ranked #2 in Science Magazine’s 2022 Top Employer survey, marking the fourth year Alnylam was featured as one of the top three companies.
  • Alnylam intends to report preliminary topline results from the Phase 1 study of ALN-APP in patients with early onset Alzheimer’s Disease.
  • Financial Results for the Quarter and Year Ended December 31, 2022

Butterfly Needles Market Report 2023: Advantages Over Straight Needles Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023
Medical Supplies, Health, US Census Bureau International Data Base, World Heart Federation, Blood, Cancer, Hospital, LDL, Vein, Patient, Needle, World Health Organization, Blood transfusion, Trauma, Diabetes, United States Census Bureau, Risk, IV, Application, WHO, Death, Stroke, Shock (mechanics), Survival, Plasma, Growth, Kent, Anti-transglutaminase antibodies, Conditional sentence, Prevalence, Chronic Respiratory Disease, COVID-19, Kidney, Vaccine, Pharmaceutical industry

The "Butterfly Needles Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Butterfly Needles Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application and End User" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the global butterfly needles market is driven by the rise in the prevalence of chronic diseases and the advantages of butterfly needles over straight needles.
  • However, the risk associated with butterfly needles stick injuries is hampering the market growth.
  • Based on application, the butterfly needles market is categorized into blood collection, IV rehydration, delivery of medications, venipuncture, and blood transfusion.

Global Canned Tuna Market Report 2022 to 2027: Players Include Golden Prize Canning, Thai Union Group, Grupo Calvo and Wild Planet Foods - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Food, Beverage, Retail, Zinc, LDL, Heart, Manganese, Stroke, Health, System, Skin, EU28, Potassium, Maintenance, Selenium, Nutrient, FAO, Splenic infarction, Cholesterol, Protein, Growth, Cancer, Tuna, Artery, B, Antioxidant, Risk, Blood pressure, Dicarboxylic acid, Immune system, Aquaculture, Drug, Dietary supplement

It was reported that Thailand achieved double-digit growth with substantial growth in exports to the Middle-Eastern countries.

Key Points: 
  • It was reported that Thailand achieved double-digit growth with substantial growth in exports to the Middle-Eastern countries.
  • Tuna species are integral to the diets of many individuals and are also one of the most commercially valuable fish at the global level.
  • The majority of the tuna fish market consists of four major species, namely, skipjack, accounting for over half of the global total catch of tuna.
  • Significant health benefits of tuna are predicted to boost tuna consumption, further increasing the market demand during the forecast period.

New Initiative Aims to Reverse the Alarming Rise in Cardiovascular Deaths

Retrieved on: 
Wednesday, January 25, 2023
LDL, Death, Stroke, National Lipid Association, National Medical Association, Cardiovascular disease, Public policy, Policy, National Medical Research Center of Cardiology, Risk, Cancer, Public, Face, Ageing, Take, Organization, Woman, Patient, Disease, Accident, Pharmaceutical industry

WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- The number of cardiovascular deaths is on the rise again after a decades-long decline. As organizations working to advance cardiovascular health and the interests of medically underserved communities, the Foundation of the National Lipid Association and the National Medical Association are launching the Take Health to Heart initiative to reverse this alarming trend.

Key Points: 
  • WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- The number of cardiovascular deaths is on the rise again after a decades-long decline.
  • Cardiovascular disease kills more people each year than all forms of cancer and accidents combined – making it the nation's leading cause of death.
  • Despite our knowledge of risk factors and advances in treatment, over 800,000 Americans still die from cardiovascular disease each year.
  • The rate of premature deaths has also increased over the last decade, with cardiovascular disease now accounting for one in five deaths among Americans aged 25 to 64 years.

Add California Prunes to daily meals and snacks to benefit your bones, heart, and digestive health

Retrieved on: 
Tuesday, January 31, 2023
Egg, Health, Nutrient, Journal, Antioxidant, Heart, Pulse, Carbohydrate, Magnesium, Water, Eating, Electrolyte, LDL, Neochlorogenic acid, Prune, HDL, Snack, Vitamin K, Chlorogenic acid, Butter, Boron, K2, Food science, Defecation, Journal of Medicinal Food, Woman, Overalls, Vitamin, Sorbitol, Cooking, Seed, Bone loss, Perspiration, Potassium, Nut, Inflammation, Rosenbloom, Viticulture, Silviculture, Dietary supplement

Filled with fibre, vitamins and antioxidants, California prunes are an important functional food to add to your favourite meals and snacks.

Key Points: 
  • Filled with fibre, vitamins and antioxidants, California prunes are an important functional food to add to your favourite meals and snacks.
  • Prunes have a low glycemic index (29), meaning they won’t cause a dramatic spike in blood sugar levels.
  • Dietitian Cara Rosenbloom explains that this beneficial effect is likely due to the combination of the nutrients found in prunes.
  • California Prunes play an important role in digestive health and are well known for their laxative effect.

NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy

Retrieved on: 
Tuesday, January 17, 2023
Cardiovascular Research, Public health, CETP, Safety, LDL, Patient, NAMS, Baylor College of Medicine, Research, Ezetimibe, Baylor University, Moyamoya disease, FESC, Pharmaceutical industry

NAARDEN, the Netherlands and MIAMI, Jan. 17, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS) (“NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced topline results from ROSE2, a Phase 2 clinical trial evaluating obicetrapib, the company’s oral, low-dose and once-daily cholesteryl ester transfer protein (“CETP”) inhibitor, in combination with ezetimibe as an adjunct to high-intensity statin therapy.

Key Points: 
  • Based on the encouraging results observed, NewAmsterdam is now selecting a formulated fixed-dose combination tablet of obicetrapib plus ezetimibe, a non-statin oral LDL-lowering therapy, to be tested in a definitive bioequivalence trial and a Phase 3 safety and efficacy trial.
  • “Today, patients – especially those at high-risk – are typically treated with very high-dose statin therapy, which can be associated with intolerable side effects that limit adherence.
  • A total of 119 patients were randomized to receive combination therapy, obicetrapib 10 mg or placebo for an 84-day treatment period.
  • Overall, the combination of obicetrapib and ezetimibe was observed to be well-tolerated, with a safety profile observed to be comparable to placebo.